From the 2018 midterm election results to the rise of CBD, Michael McGuffin, president of the American Herbal Products Association, talks about how the association is approaching the most recent changes in the supplements space.
By Elena Nekrasov, PhD, Senior Regulatory Scientist, Access Business Group, Amway
Getting your regulatory affairs department or a consultant involved early in the development process can save multiple headaches later when bringing new products to market. The global regulatory goalposts are moving all the time, and R&D teams need...
The Natural Products Association’s stance on CBD is to take FDA’s word on the controversial ingredient, until someone takes the front door with the Agency and files an NDI or a GRAS notification with the FDA for CBD.
The low barriers to entry in the dietary supplement industry create the risk that the good deeds of the many will be besmirched by the transgressions of the few. Fortunately, there is something that can be done about it, given enough collective will.
“Just because we haven’t taken enforcement action people seem to think it [CBD] is OK,” said Steven Tave, director of the FDA’s Office of Dietary Supplement Programs, at a recent industry conference. “Anyone who thinks it is lawful is mistaken.”
Companies seeking to commercialise a probiotic product across the globe face a 'daunting task', which is why trade association the International Probitics Association (IPA) is vowing not to let up in its efforts to achieve a more consistent...
Amarin Corporation, maker of EPA drug Vascepa, has sued two omega-3s finished good manufacturers for unfair trade practices for allegedly using the results of the company’s large scale drug trial to market their own fish-oil based dietary supplements.
The Nagoya Protocol, the big changes coming for Lactobacillus classification, and how to boost your chances of success with an NDI notification were just some of the topic covered during the third annual IPA Workshop in DC.